FDA Clears New Neurostimulation System for Chronic Pain

The US Food and Drug Administration has approved the Proclaim Plus spinal cord stimulation system with FlexBurst360 therapy, which provides personalized coverage at up to six pain points.
FDA Approvals

source https://www.medscape.com/viewarticle/979612?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost